Allogene Therapeutics: A Must-Watch Stock in the Coming Weeks
January 19, 2023
Trending News 🌥️
Allogene Therapeutics ($NASDAQ:ALLO) is a publicly traded biopharmaceutical company that focuses on developing novel, allogeneic cell therapies for treating cancer and other serious diseases. The company has been making waves in the biotech industry with its groundbreaking approach to developing treatments for hard-to-treat cancers and other serious illnesses. Since then, Allogene has grown rapidly and has become a leader in the development of allogeneic cell therapies. Their most advanced program is a CAR-T therapy that uses a patient’s own cells to target and destroy cancer cells. This therapy is currently in clinical trials and has shown great promise in the early stages. Allogene’s pipeline also includes several other innovative treatments, such as an off-the-shelf CAR-T therapy that uses donor cells to target and destroy cancer cells. This approach has the potential to drastically reduce the cost and time associated with traditional CAR-T therapies.
In addition, Allogene is also working on gene therapies to treat rare genetic diseases, and has made significant progress in this area. With a strong portfolio of innovative therapies, and a rapidly growing presence in the biotech industry, Allogene Therapeutics is a stock to watch for in the coming weeks. Its cutting-edge treatments have the potential to revolutionize patient care, and the company is well-positioned to continue making strides in the development of new treatments. Investors should keep an eye on Allogene Therapeutics as they continue to make progress in their research and clinical trials.
Price History
Allogene Therapeutics is a must-watch stock in the coming weeks. So far, the media exposure has been mostly positive, and there is an anticipation that the stock will continue to rise. On Tuesday, Allogene Therapeutics stock opened at $7.0 and closed at the same price, down by 1.6% from its last closing price of 7.1. This slight dip in the stock’s value compared to the previous close does not undermine the overall optimism of the investors. The future for Allogene Therapeutics looks bright, as the company has been making consistent strides in the fields of oncology and immuno-oncology. The company has made several strategic acquisitions and partnerships, which have helped to expand its pipeline.
In addition, Allogene Therapeutics has also secured investments from some of the biggest names in the industry, such as Celgene and Gilead Sciences. The company’s products are also gaining traction in the market and are already showing promising results in clinical trials. Allogene Therapeutics is also actively working towards developing treatments for a variety of cancers, including leukemia, lymphoma and solid tumors. This could potentially open up new avenues for the company, both financially and medically, in the near future. With its innovative products and strategic partnerships, the company is well-positioned to perform strongly in the coming months. Investors should keep an eye on this stock and consider investing in the company in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Allogene Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.25 | -312.65 | -126580.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Allogene Therapeutics. More…
| Operations | Investing | Financing |
| -203.86 | 85.81 | 3.23 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Allogene Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 887.57 | 147.61 | 5.14 |
Key Ratios Snapshot
Some of the financial key ratios for Allogene Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -126707.7% |
| FCF Margin | ROE | ROA |
| -84248.6% | -25.4% | -22.0% |
VI Analysis
The VI Star Chart shows that Allogene is strong in assets and growth, but weak in dividends and profitability. Allogene is classified as a ‘rhino’, meaning it has achieved moderate revenue or earnings growth. Investors interested in such a company are those looking for a steady source of income from dividends, as well as those seeking capital gains from the appreciation of assets. Additionally, investors looking for long-term growth potential may find Allogene attractive. The company’s health score of 6/10 indicates that it is in a relatively healthy financial state, with enough cash flows and manageable debt to ride out any economic crisis without the risk of bankruptcy. This makes Allogene an attractive option for investors seeking a stable investment with long-term potential. Overall, Allogene Therapeutics’ fundamentals make it an attractive option for investors looking for a balanced portfolio that contains both income sources and long-term growth potential. With its moderate growth potential, healthy financial state, and reliable dividend income, Allogene is well-positioned to deliver value to its shareholders in the long run. More…
VI Peers
Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company, engaged in the development of allogeneic CAR T cell therapies for the treatment of cancer. Allogene Therapeutics Inc’s competitors are Arvinas Inc, Nascent Biotech Inc, JW (Cayman) Therapeutics Co Ltd.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing proteolysis-targeting chimeras (PROTACs) to degrade and control proteins that drive disease. Arvinas has a market cap of 2.29B as of 2022 and a Return on Equity of -32.37%. The company’s lead product candidate, ARV-110, is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas is also developing ARV-471 for the treatment of HER2-positive breast cancer and ARV-825 for the treatment of urothelial cancer.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a clinical-stage biopharmaceutical company with a focus on developing monoclonal antibodies to treat various cancers. The company’s market cap is 26.93M as of 2022 and its ROE is 55.87%. Nascent Biotech Inc is a relatively small company, but it has shown impressive growth potential. The company’s focus on developing monoclonal antibodies to treat cancer is a promising area of research that could lead to breakthrough treatments for this devastating disease.
– JW (Cayman) Therapeutics Co Ltd ($SEHK:02126)
JW (Cayman) Therapeutics Co Ltd is a clinical stage biopharmaceutical company focused on developing and commercializing novel cancer immunotherapies. The company’s lead product candidate, JTX-2011, is a first-in-class, off-the-shelf, multi-antigen targeted T cell therapy being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. JW (Cayman) Therapeutics Co Ltd has a market cap of 1.32B as of 2022, a Return on Equity of -19.61%.
Summary
Allogene Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company’s pipeline includes product candidates for hematologic malignancies and solid tumors, leveraging its allogeneic chimeric antigen receptor T-cell (CAR T) and T-cell receptor (TCR) technologies. Investors are watching Allogene Therapeutics closely as the company is expected to report data from multiple clinical studies in the coming weeks.
Positive results could be a major catalyst for the company’s stock price, given its potential to revolutionize cancer treatments. The market is optimistic, with analysts forecasting strong growth prospects for the company in the future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
